{"id":"cik-cell","safety":{"commonSideEffects":[{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4298070","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CIK cells are a type of immune cell that can recognize and kill cancer cells. They work by activating the immune system to produce cytokines, which help to eliminate cancer cells. This approach is often used in the treatment of various types of cancer.","oneSentence":"CIK cells are a type of adoptive cell therapy that stimulate the immune system to attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:47.105Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various types of cancer, including leukemia, lymphoma, and solid tumors"}]},"trialDetails":[{"nctId":"NCT06389305","phase":"NA","title":"CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-05-27","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia","enrollment":213},{"nctId":"NCT07343791","phase":"EARLY_PHASE1","title":"Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","status":"RECRUITING","sponsor":"JIANG LONGWEI","startDate":"2025-11-19","conditions":"DC-CIK Treatment, Regorafenib, Colorectal Cancer","enrollment":14},{"nctId":"NCT07271446","phase":"PHASE1","title":"An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer","status":"COMPLETED","sponsor":"Precision Biotech Taiwan Corp.","startDate":"2018-09-01","conditions":"Non-small Cell Lung Cancer","enrollment":8},{"nctId":"NCT07260058","phase":"PHASE1, PHASE2","title":"Immune Cell Therapy for Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","startDate":"2025-12-01","conditions":"Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)","enrollment":48},{"nctId":"NCT07204496","phase":"","title":"A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-09-26","conditions":"Advanced Bladder Cancer","enrollment":20},{"nctId":"NCT04836728","phase":"PHASE2","title":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-31","conditions":"Non-small Cell Lung Cancer Metastatic, First-line Treatment","enrollment":156},{"nctId":"NCT01868490","phase":"PHASE1, PHASE2","title":"The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells","status":"ENROLLING_BY_INVITATION","sponsor":"Siriraj Hospital","startDate":"2009-04-17","conditions":"Cholangiocarcinoma, Neuroblastoma","enrollment":20},{"nctId":"NCT06684899","phase":"","title":"Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-11","conditions":"Glioblastoma, Cytokine-Induced Killer Cells","enrollment":40},{"nctId":"NCT06643221","phase":"EARLY_PHASE1","title":"Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2018-01-24","conditions":"Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion","enrollment":100},{"nctId":"NCT01898663","phase":"PHASE1, PHASE2","title":"DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-06","conditions":"High-risk Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT05268172","phase":"PHASE1","title":"IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites","status":"RECRUITING","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":"Pleural Effusion, Malignant","enrollment":40},{"nctId":"NCT05869279","phase":"PHASE1, PHASE2","title":"Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","startDate":"2023-12-01","conditions":"B-cell NHL, CLL","enrollment":29},{"nctId":"NCT04282044","phase":"PHASE1","title":"Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"BioEclipse Therapeutics","startDate":"2021-01-08","conditions":"Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT03757858","phase":"PHASE1, PHASE2","title":"Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2018-03-01","conditions":"Cancer, Abdominal Cancer, Pelvic Cancer","enrollment":40},{"nctId":"NCT03393858","phase":"PHASE1, PHASE2","title":"Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma","status":"TERMINATED","sponsor":"Capital Medical University","startDate":"2017-12-01","conditions":"Cancer, Mesothelioma, Malignant","enrollment":10},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT01884168","phase":"","title":"Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-03","conditions":"Malignant Tumor","enrollment":30},{"nctId":"NCT03190811","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-09","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT03360630","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-11-01","conditions":"Lung Cancer, Neoplasms","enrollment":60},{"nctId":"NCT01898793","phase":"PHASE1, PHASE2","title":"Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2014-08-11","conditions":"Leukemia, Myeloid, Acute","enrollment":89},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT00699816","phase":"PHASE3","title":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2008-07","conditions":"Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT03983967","phase":"PHASE1, PHASE2","title":"Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2019-01-24","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT02856815","phase":"PHASE2","title":"Safety and Efficacy of \"Immuncell-LC\" in TACE Therapy","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2018-05-28","conditions":"Carcinoma, Hepatocellular","enrollment":76},{"nctId":"NCT03389035","phase":"PHASE1, PHASE2","title":"Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT","status":"COMPLETED","sponsor":"Fondazione Matilde Tettamanti Menotti De Marchi Onlus","startDate":"2017-12-20","conditions":"Acute Lymphoblastic Leukemia, in Relapse","enrollment":21},{"nctId":"NCT04802070","phase":"PHASE1","title":"Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.","status":"COMPLETED","sponsor":"Prof. Franca Fagioli","startDate":"2021-01-11","conditions":"Sarcoma","enrollment":7},{"nctId":"NCT04214717","phase":"NA","title":"Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Yantai Yuhuangding Hospital","startDate":"2019-12-31","conditions":"Solid Tumor","enrollment":60},{"nctId":"NCT05676190","phase":"NA","title":"Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer","status":"RECRUITING","sponsor":"ShiCang Yu","startDate":"2023-01-09","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT05622825","phase":"PHASE1, PHASE2","title":"Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-01","conditions":"Advanced Liver Cancers","enrollment":15},{"nctId":"NCT02752243","phase":"PHASE1, PHASE2","title":"CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.","status":"UNKNOWN","sponsor":"Peter Bader","startDate":"2016-03","conditions":"Myelodysplastic Syndromes, Acute Leukemia","enrollment":32},{"nctId":"NCT05108077","phase":"PHASE1, PHASE2","title":"Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells","status":"UNKNOWN","sponsor":"Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","startDate":"2022-03-01","conditions":"Bladder Cancer, Renal Cancer","enrollment":20},{"nctId":"NCT03821519","phase":"PHASE1, PHASE2","title":"Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant","status":"UNKNOWN","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2019-01-13","conditions":"Relapsed Hematologic Malignancy","enrollment":20},{"nctId":"NCT05020119","phase":"PHASE1","title":"Neoantigen-expanded Autologous Immune Cell Therapy","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-04-09","conditions":"Advanced Solid Tumor","enrollment":9},{"nctId":"NCT02621333","phase":"PHASE2","title":"Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2015-10","conditions":"Lung Adenocarcinoma","enrollment":280},{"nctId":"NCT03329664","phase":"PHASE1, PHASE2","title":"Autologous Killer Cell Therapy in Colon Cancer Patients","status":"UNKNOWN","sponsor":"Sabz Biomedicals","startDate":"2020-02-09","conditions":"Colon Cancer Stage IV","enrollment":20},{"nctId":"NCT02851784","phase":"PHASE2, PHASE3","title":"Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2009-12","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT03146637","phase":"PHASE2","title":"Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","startDate":"2017-05-01","conditions":"Advanced Liver Cancer","enrollment":80},{"nctId":"NCT03782363","phase":"PHASE1","title":"Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.","status":"WITHDRAWN","sponsor":"Italian Sarcoma Group","startDate":"2020-12-18","conditions":"Sarcoma","enrollment":""},{"nctId":"NCT03524274","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-05","conditions":"Advanced Colorectal Cancer","enrollment":""},{"nctId":"NCT03509298","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-12","conditions":"Advanced Pancreatic Cancer","enrollment":""},{"nctId":"NCT03501056","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-03-27","conditions":"Advanced Lung Cancer","enrollment":""},{"nctId":"NCT03540199","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-10","conditions":"Advanced Kidney Cancer","enrollment":""},{"nctId":"NCT03484962","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-03-25","conditions":"Advanced Liver Cancer","enrollment":""},{"nctId":"NCT03524261","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2019-05-20","conditions":"Advanced Breast Cancer","enrollment":""},{"nctId":"NCT03554395","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-05","conditions":"Advanced Gastric Cancer","enrollment":""},{"nctId":"NCT04476641","phase":"PHASE2","title":"A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-05-06","conditions":"Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer","enrollment":686},{"nctId":"NCT03987867","phase":"PHASE1","title":"Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer, First-line Treatment","enrollment":30},{"nctId":"NCT03987698","phase":"PHASE2","title":"Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":90},{"nctId":"NCT03983759","phase":"PHASE2","title":"Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2019-06-20","conditions":"Small Cell Lung Cancer, Extensive Disease, Adoptive Cellular Immunotherapy","enrollment":40},{"nctId":"NCT03002831","phase":"PHASE2","title":"Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2016-11","conditions":"Advanced Cancer","enrollment":13},{"nctId":"NCT04292769","phase":"PHASE3","title":"Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors","status":"UNKNOWN","sponsor":"Li Yu","startDate":"2020-01-21","conditions":"Malignant Neoplasm","enrollment":200},{"nctId":"NCT02585908","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of γδ T Cell Against Gastric Cancer","status":"UNKNOWN","sponsor":"Beijing Doing Biomedical Co., Ltd.","startDate":"2019-12","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT01631357","phase":"PHASE2, PHASE3","title":"Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-12","conditions":"Non-small Cell Lung Cancer, Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT01691664","phase":"NA","title":"Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Cancer","enrollment":40},{"nctId":"NCT02425748","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2017-06-08","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT03944980","phase":"PHASE3","title":"Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"IIIB/IIIC/IV Lung Cancer","enrollment":146},{"nctId":"NCT01392989","phase":"PHASE2","title":"Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders","status":"COMPLETED","sponsor":"Everett Meyer","startDate":"2011-03","conditions":"Neural Tube Defects, Anemia, Leukemia, Myeloid","enrollment":44},{"nctId":"NCT03815630","phase":"EARLY_PHASE1","title":"A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Allife Medical Science and Technology Co., Ltd.","startDate":"2019-02-01","conditions":"Solid Tumor","enrollment":100},{"nctId":"NCT01186809","phase":"PHASE2","title":"Cytokine Induced Killer (CIK) Cells In Leukemia Patients","status":"COMPLETED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2009-07","conditions":"Hematologic Malignancies","enrollment":74},{"nctId":"NCT03736330","phase":"PHASE2","title":"A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-09-08","conditions":"Renal Cancer Metastatic","enrollment":24},{"nctId":"NCT01783951","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-02-01","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT01894373","phase":"PHASE1, PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2015-06","conditions":"Psoriasis, Adoptive Immunotherapy","enrollment":10},{"nctId":"NCT01781520","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-06-01","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT03282435","phase":"PHASE1","title":"Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody","status":"UNKNOWN","sponsor":"Dalian University","startDate":"2018-01","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT02482454","phase":"PHASE2, PHASE3","title":"Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2012-07","conditions":"Cholangiocarcinoma","enrollment":50},{"nctId":"NCT03220984","phase":"PHASE2","title":"The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2017-03-16","conditions":"Metastatic Colorectal Cancer","enrollment":28},{"nctId":"NCT03158480","phase":"NA","title":"Safety and Efficacy of Immune Therapy for Condyloma","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2017-06-25","conditions":"Condylomata Acuminata","enrollment":80},{"nctId":"NCT02568748","phase":"PHASE3","title":"Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2015-10","conditions":"Liver Cancer","enrollment":20},{"nctId":"NCT03124498","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA","status":"UNKNOWN","sponsor":"Chuan An Biotechnology Co., Ltd.","startDate":"2017-11","conditions":"Hepatocellular Carcinoma","enrollment":55},{"nctId":"NCT03084809","phase":"PHASE4","title":"Chemotherapy Combined With CIK Treating Colon Cancer","status":"COMPLETED","sponsor":"China Meitan General Hospital","startDate":"2012-05-06","conditions":"Colorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications","enrollment":46},{"nctId":"NCT03057340","phase":"PHASE1","title":"The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-06-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT00394381","phase":"PHASE1, PHASE2","title":"Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, High Grade","enrollment":17},{"nctId":"NCT00815321","phase":"PHASE2","title":"Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2008-12","conditions":"Chronic Myeloid Leukemia","enrollment":11},{"nctId":"NCT00460694","phase":"PHASE1, PHASE2","title":"Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia","enrollment":24},{"nctId":"NCT03047525","phase":"PHASE1, PHASE2","title":"Study of DC-CTL Combined With CIK for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Xiaoyi Huang","startDate":"2017-02-20","conditions":"Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT00477035","phase":"PHASE1","title":"Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies","status":"COMPLETED","sponsor":"Sally Arai","startDate":"2006-05","conditions":"Leukemia, Multiple Myeloma","enrollment":22},{"nctId":"NCT02886897","phase":"PHASE1, PHASE2","title":"A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-07","conditions":"Hepatocellular Carcinoma, Renal Cell Carcinoma, Bladder Cancer","enrollment":50},{"nctId":"NCT02539017","phase":"PHASE2","title":"The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2015-11","conditions":"Triple Negative Breast Neoplasms","enrollment":""},{"nctId":"NCT02418481","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02425735","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Liver Cancer","enrollment":40},{"nctId":"NCT02215837","phase":"PHASE2","title":"Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-08","conditions":"Gastric Cancer, Neoplasms, Gastrointestinal Neoplasms","enrollment":40},{"nctId":"NCT02487017","phase":"PHASE2","title":"DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2015-05","conditions":"Hepatocellular Carcinoma, Neoplasms, Digestive System Neoplasms","enrollment":60},{"nctId":"NCT02651441","phase":"PHASE1, PHASE2","title":"D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2016-02","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT02644863","phase":"PHASE2","title":"Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2015-12","conditions":"Esophageal Neoplasms, Neoplasms, Digestive System Neoplasms","enrollment":60},{"nctId":"NCT01749865","phase":"PHASE3","title":"CIK Treatment for HCC Patient Underwent Radical Resection","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-10","conditions":"Carcinoma, Hepatocellular","enrollment":200},{"nctId":"NCT00769106","phase":"PHASE3","title":"Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-06","conditions":"Hepatocellular Carcinoma","enrollment":200},{"nctId":"NCT02693236","phase":"PHASE1, PHASE2","title":"DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-08","conditions":"Esophagus Cancer","enrollment":30},{"nctId":"NCT02412384","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":120},{"nctId":"NCT02487992","phase":"PHASE2","title":"The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-07","conditions":"Colorectal Neoplasms","enrollment":1200},{"nctId":"NCT02491697","phase":"PHASE2","title":"Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2016-02","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02688673","phase":"PHASE1, PHASE2","title":"DC Vaccine Combined With CIK Cells in Patients With SCLC","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-08","conditions":"Small- Cell Lung Cancer","enrollment":30},{"nctId":"NCT02490748","phase":"PHASE2","title":"Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-07","conditions":"Cervical Cancer","enrollment":10},{"nctId":"NCT02487693","phase":"PHASE2","title":"Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-07","conditions":"Ovarian Carcinoma","enrollment":50},{"nctId":"NCT02688686","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2016-02","conditions":"Non-Small-Cell Lung Cancer With Bone Metastases","enrollment":30},{"nctId":"NCT01924156","phase":"PHASE1, PHASE2","title":"DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-07","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT02489890","phase":"PHASE2","title":"CIK in Treating Patients With Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2016-02","conditions":"Urinary Bladder Neoplasms","enrollment":1500},{"nctId":"NCT01956630","phase":"PHASE1, PHASE2","title":"Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-09","conditions":"Acute Leukemia","enrollment":25},{"nctId":"NCT02485015","phase":"PHASE2","title":"The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-06","conditions":"Stomach Neoplasms","enrollment":80},{"nctId":"NCT01758679","phase":"PHASE4","title":"A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-01","conditions":"Multiple Drug Use","enrollment":120},{"nctId":"NCT02493582","phase":"PHASE2","title":"The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-07","conditions":"Adenocarcinoma of Lung","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":398,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologous cytokine-induced killer cells","Cytokine-induced killer cell"],"phase":"phase_2","status":"active","brandName":"CIK Cell","genericName":"CIK Cell","companyName":"Chuan An Biotechnology Co., Ltd.","companyId":"chuan-an-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"CIK cells are a type of adoptive cell therapy that stimulate the immune system to attack cancer cells. Used for Treatment of various types of cancer, including leukemia, lymphoma, and solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}